HSPB1 and Charcot-Marie-Tooth disease: In recent years, peptide aptamers (PAs) have been developed that positively or negatively modulate the function and oligomeric status of HSPB1.36 Such PAs will likely prove to be valuable tools in the generation of chemical modulators of HSPB1, which would have implications for the treatment of several diseases including CMT and other motor neuropathies where HSPB1 mutations are involved in the disease.